Antiplatelet drugs have been shown to prevent a range of atherothrombotic events, including @entity4905 ( @entity4905 ) and @entity64 . @entity1397 and @entity1396 are @entity857 ( @entity857 )-receptor antagonists that inhibit @entity857 -induced fibrinogen binding to platelets, a necessary step in the @entity1423 process. The Antithrombotic Trialists' Collaboration recently published a major meta-analysis that assessed the effect of antiplatelet therapy in @entity1 with various manifestations of @entity731 . In total, this analysis included 135,000 @entity1 in comparisons of antiplatelet agents versus control and 77,000 @entity1 in comparisons of different antiplatelet regimens. This meta-analysis found that overall, antiplatelet therapy reduces the combined odds of @entity64 , @entity583 ( @entity583 ) or @entity204 by 22%, and that antiplatelet agents reduce the odds of a non-fatal @entity64 by 25% over a wide range of @entity1 with or without a history of @entity66 . In the CAPRIE trial of @entity1397 versus @entity117 ( @entity1281 ), there was a 10% odds reduction for @entity64 , @entity583 in favour of @entity1397 (p = 0.03). In a meta-analysis performed by the Cochrane @entity64 Group, @entity857 -receptor antagonist therapy significantly reduced the odds of a serious vascular event ( @entity64 , @entity583 ) by 9% (2p = 0.01) and of any @entity64 by 12%. The safety/tolerability profile of @entity1397 was superior to that of @entity1396 , and at least as good as that of @entity1281 . In CURE, a long-term benefit was observed with the use of @entity1397 on top of standard therapy (including @entity1281 in all @entity1 ), with a 20% relative risk reduction for the primary endpoint of @entity65 , @entity583 or @entity64 (p < 0.001) in @entity1 with @entity1459 and non-Q-wave @entity583 . A consistent benefit was seen across all @entity1 subgroups, including @entity1 with a previous history of @entity64 . More recently, CREDO has demonstrated the incremental benefit of prolonged use of @entity1397 on top of @entity1281 in @entity1 undergoing elective PCI, with a 27% reduction in the combined risk of @entity204 , @entity583 or @entity64 after 12 months of therapy (p = 0.02) and a 25% reduction in @entity64 over the same time period. The MATCH trial is currently being conducted to test the hypothesis that long-term administration of @entity1397 on top of @entity1281 is superior to @entity1397 alone for the reduction of major ischaemic events in @entity1 with recent @entity4905 or @entity64 who are at high risk of atherothrombotic recurrence. Further trials of @entity1397 on top of standard therapy (including @entity1281 ) are planned in neurology; these include SPS3, in @entity1 with small subcortical @entity64 , and ATARI, in @entity1 who have recently recovered from a @entity4905 .

Evidence with antiplatelet therapy and XXXX -receptor antagonists.

@entity1 :: ('9606', 'Species') :: ['patient', 'patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['strokes', 'ischaemic stroke', 'Stroke', 'stroke'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI or vascular death', 'MI'] @entity1396 :: ('MESH:D013988', 'Chemical') :: ['ticlopidine'] @entity1423 :: ('MESH:D001791', 'Disease') :: ['platelet aggregation'] @entity66 :: ('MESH:D004194', 'Disease') :: ['cerebrovascular disease'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['clopidogrel', 'Clopidogrel'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['acetylsalicylic acid'] @entity1281 :: ('CHEBI:15365', 'Chemical') :: ['ASA'] @entity1459 :: ('MESH:D000789', 'Disease') :: ['unstable angina'] @entity4905 :: ('MESH:D002546', 'Disease') :: ['transient ischaemic attack', 'TIA'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis'] @entity857 :: ('MESH:D000244', 'Chemical') :: ['adenosine diphosphate', 'ADP'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death', 'vascular death'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular death']
@entity857 :: (MESH:D000244,Chemical) :: ['ADP']
